Koers aTyr Pharma Inc Nasdaq
Aandelen
US0021201035
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 2,7 mln. 2,51 mln. | Omzet 2025 * | 12,34 mln. 11,47 mln. | Marktkapitalisatie | 109 mln. 102 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -58 mln. -53,9 mln. | Nettowinst (verlies) 2025 * | -59 mln. -54,83 mln. | EV/omzet 2024 * | 40,5 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 8,86 x |
K/w-verhouding 2024 * |
-2,09
x | K/w-verhouding 2025 * |
-2,04
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,38% |
Recentste transcriptie over aTyr Pharma Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 30-03-16 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 30-07-18 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | 01-06-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 08-09-05 |
Tim Coughlin
CHM | Chairman | 57 | 10-04-17 |
John Clarke
BRD | Director/Board Member | 70 | 01-09-05 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 48,09 mld. | |
+46,90% | 40,62 mld. | |
-3,46% | 40,43 mld. | |
-6,20% | 28,36 mld. | |
+9,17% | 24,89 mld. | |
-20,42% | 19,01 mld. | |
+28,07% | 12,09 mld. | |
+0,17% | 11,88 mld. | |
-1,24% | 11,8 mld. |